Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.18.7835

Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival  

Sadighi, Sanambar (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences)
Roshanaee, Ghodratollah (Biostatistics Department, Hamadan University of Medical Sciences)
Vahedi, Saba (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences)
Jahanzad, Easa (Department of Pathology, Cancer Research Center, Tehran University of Medical Sciences)
Mohagheghi, Mohammad Ali (Department of Surgical Oncology, Cancer Research Center, Tehran University of Medical Sciences)
Mousavi-Jarahi, Alireza (Department of Social Medicine, Shahid Beheshti University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.18, 2014 , pp. 7835-7838 More about this Journal
Abstract
Background: Neuroendocrine tumors have widespread and different clinical presentations and prognoses. This study was conducted to assess their survival time and prognostic factors in Iran. Materials and Methods: In a retrospective cohort study, 189 patients diagnosed of having neuroendocrine carcinoma were chosen. The tumor and clinical characteristics of the patients were modeled with a Cox proportional hazard approach. Survival was assessed using Kaplan-Meyer curves. Results: Crude median survival time was 30 months. Women survived longer than men (the median survival time for women was 40 and for men was 24 months). Age (<60 vs >60 years old with hazard ratio (HR) of 2.43, 95% CI 1.3-4.5), primary pathology report (carcinoid vs. others with HR 5.85 cm, 95% CI 2.4-14.3), tumor size cm (for 5-10, HR of 3.1, 95% CI 1.6 and for >10 HR of 8.2, 95% with 95% CI 3.1-21.9), and chemotherapy with single drug (taking vs. not taking with a HR 2.2, 95% CI 1.1-4.8) had significant effects on overall survival of patients. Conclusions: Survival time in patients with neuroendocrine carcinomas is related to demographics, clinical characteristics, tumor histology, and subtype specific treatment.
Keywords
Neuroendocrine neoplasms; carcinoid tumors; survival; Cox proportional hazard model; chemotherapy;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Al-khafaji B, Noffsinger A, Miller M, et al (1999). Immunohistologic analysis of GI and pulmonary carcinoid tumors. Hum Pathol, 29, 992.
2 Bernick P, Klimstra S, Shia Jea (2004). Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum, 47, 163-9.   DOI   ScienceOn
3 Brenner B, Shah M, Gonen M (2004). Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer, 90, 1720-6.
4 Galanis E, Frytak S, Lloyd R (1997). Extrapulmonary small cell carcinoma. Cancer, 79, 1729-36.   DOI
5 Demirci U, Coskun U, Karaca H, et al (2014). Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15, 1581-4.   과학기술학회마을   DOI   ScienceOn
6 Durante C, Boukheris H, Dromain C, et al (2009). Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer, 16, 585-97.   DOI   ScienceOn
7 Fujii H, Aotake T, Horiuchi T et al (2001). Small cell carcinoma of the gallbladder: a case 45 report and review of 53 cases in the literature. Hepatogastroenterology, 48, 1588-93.
8 Garcia-Carbonero R, Capdevila J, Crespo-Herrero G (2010). Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the national cancer registry of Spain (RGETNE). Ann Oncol, 21, 1794-803.   DOI   ScienceOn
9 Harkema J, Jones S, Naydan D, Wilson D (1992). An atypical neuroendocrine carcinoma in the lung of a beagle dog. Vet Pathol, 29, 175-9.   DOI   ScienceOn
10 Junker K, Wiethege T, Muller K (2000). Pathology of small-cell lung cancer. J cancer Res clin oncol, 7, 361-8.
11 Kang H, O'Connell J, Leonardi M (2007). Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis, 22, 183-9.
12 Kulve M, Mayer R (1999). Carcinoid tumors. N Engl J Med, 340, 858-68.   DOI   ScienceOn
13 Lee S, Lee J, Ryu M (2007). Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol, 46, 846-51.   DOI   ScienceOn
14 Moertel C, Kvols L, O'Connell M (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68, 227-32.   DOI
15 Medrano-Guzman R, Lopez-Garcia SC, Torres-Vargas S, Gonzalez-Rodriguez D, Alvarado-Cabrero I (2011). Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival. Cirugia y Cirujanos, 79, 459-564.
16 Modlin I, Lye K, Kidd M (2003). A 5-decade analysis of 13, 715 carcinoid tumors. Cancer, 97, 934-59.   DOI   ScienceOn
17 Modlin I, Oberg K, Chung D, et al (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9, 61-72.   DOI   ScienceOn
18 Wang Y-h, Lin Y, Xue L, et al (2012). Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord, 12, 30-9.   DOI   ScienceOn
19 Sadighi S, Jahanzad I, Ghadirian L, et al (2013). Assessing the prevalence and characteristics of neuroendocrine tumors in patients attending Tehran Imam Khomeiny referral hospital. J Mazand Univ Med Sci, 23, 232-6.
20 Sorbye H, Welin S, Langer SW, et al (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol, 24, 152-60.   DOI   ScienceOn
21 Wu B, Hu Y, Sun J, et al (2014). Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors. Asian Pac J Cancer Prev, 15, 2205-10.   과학기술학회마을   DOI   ScienceOn
22 Yao J, Hassan M, Phan A, et al (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26, 3063-72.   DOI   ScienceOn
23 Yocel B, Babakan NAKanan T, Ayeren A (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92.   과학기술학회마을   DOI   ScienceOn
24 Zeng YJ, Liv L, We H, et al (2013). Clinicopathologic features and prognosis of GIP neuroendocrine tumors:Analysis from a single institution. Asian Pac J Cancer Prev, 14, 5775-81.   DOI   ScienceOn